Through two new clinical trials, researchers at the University of Wisconsin-Madison hope to better understand how opioid and methamphetamine addictions can be treated using a different drug: psilocybin.

In recent years, psilocybin has generated renewed interest from scientists as a promising mental health treatment, and Oregon became the first state to legalize adult use of the drug on Jan. 1. Studies have also already shown therapy in conjunction with psilocybin, the psychedelic chemical found in magic mushrooms, is effective in curbing dependence to alcoholtobacco and cocaine.

But the studies from the Transdisciplinary Center for Research in Psychoactive Substances (TCRPS), part of UW-Madison’s School of Pharmacy, enter into new territory by studying the drug’s effects on people who misuse opioids and methamphetamine.